Studying People With Obesity Offered Weight-Loss Medicine
Follows people with obesity who are offered weight-loss medicine.
Plain-language title generated from the registry record
Registry title: Characterization and Phenotyping of Patients Who Are Offered Drug Therapy for Obesity
Key facts
- Where
- Bologna, ItalySee the site
Where in Italy
- IRCCS Azienda Ospedaliero-Universitaria di BolognaBologna, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Trial code
- NCT07414043
- Record updated
- 17 February 2026
- Original description
The study is multicenter and observational, consisting of a cross-sectional phase (V0) in which data will be collected from patients who are offered drug therapy, and a prospective longitudinal phase in which only patients who agree to start drug therapy for obesity will be involvedRead full original descriptionShow less
391/2025/OssF/AOUBo
The study is multicenter and observational, consisting of a cross-sectional phase (V0) in which data will be collected from patients who are offered drug therapy, and a prospective longitudinal phase in which only patients who agree to start drug therapy for obesity will be involved
Inclusion: Therapeutic indication for taking one of the following drugs for the treatment of obesity: Orlistat, Naltrexone/Bupropion (Mysimba®), Liraglutide (Saxenda®), Semaglutide (Wegovy®), Tirzepatide (Mounjaro®).
Exclusion: Endocrinopathies associated with obesity (Cushing's syndrome, uncompensated hypothyroidism); Secondary forms of obesity:; Hypothalamic obesity (both monogenic and acquired forms); Syndromic obesity (e.g., Prader-Willi, Alstrom, Bardet Biedl, etc.).